Literature DB >> 10146911

Indirect costs in economic studies: confronting the confusion.

M A Koopmanschap1, F F Rutten.   

Abstract

Indirect costs of disease often constitute a substantial part of estimated costs or savings in economic evaluations of healthcare programmes. The human capital approach is almost unanimously used for estimating indirect costs, defined as production loss due to disease, although a growing number of authors question its validity. This article discusses the relevance of indirect cost estimates for health policy and reviews the current empirical and methodological literature on this issue. It describes several important issues and controversies regarding indirect costs, such as the consequences of short term absence from work for productivity, reduced productivity without absence from work, the influence of unemployment on production loss, the relation between health effects and indirect costs, and the possible medium term macroeconomic consequences of absence from work and disability. It concludes that indirect costs are relevant for health policy, provided that the estimates of indirect costs reflect the real changes in production due to disease, including the production of unpaid labour. Future research should focus on attaining these estimates. Indirect costs in economic evaluations should preferably be presented separately from direct costs, health effects and other study outcomes.

Entities:  

Mesh:

Year:  1993        PMID: 10146911     DOI: 10.2165/00019053-199304060-00006

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  41 in total

1.  An economic evaluation of asthma in the United States.

Authors:  K B Weiss; P J Gergen; T A Hodgson
Journal:  N Engl J Med       Date:  1992-03-26       Impact factor: 91.245

2.  The cost-effectiveness of routine post myocardial infarction exercise stress testing.

Authors:  A Laupacis; R Labelle; R Goeree; J Cairns
Journal:  Can J Cardiol       Date:  1990-05       Impact factor: 5.223

3.  Randomized controlled study of a retiree health promotion program. The Bank of American Study.

Authors:  J P Leigh; N Richardson; R Beck; C Kerr; H Harrington; C L Parcell; J F Fries
Journal:  Arch Intern Med       Date:  1992-06

4.  Towards a new approach for estimating indirect costs of disease.

Authors:  M A Koopmanschap; B M van Ineveld
Journal:  Soc Sci Med       Date:  1992-05       Impact factor: 4.634

5.  Cost-benefit analysis of an educational program for general practitioners by the Swedish Committee for the Prevention and Treatment of Depression.

Authors:  W Rutz; P Carlsson; L von Knorring; J Wålinder
Journal:  Acta Psychiatr Scand       Date:  1992-06       Impact factor: 6.392

6.  Childhood injuries in the United States. Mortality, Morbidity, and cost.

Authors:  B Guyer; B Ellers
Journal:  Am J Dis Child       Date:  1990-06

7.  Economics of coronary artery bypass grafting.

Authors:  A Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-03

8.  A question of value: measuring the impact of chronic disease.

Authors:  D P Lubeck; E H Yelin
Journal:  Milbank Q       Date:  1988       Impact factor: 4.911

9.  Cost of and payment source for pelvic inflammatory disease. Trends and projections, 1983 through 2000.

Authors:  A E Washington; P Katz
Journal:  JAMA       Date:  1991-11-13       Impact factor: 56.272

10.  The economic cost of senile dementia in the United States, 1985.

Authors:  L F Huang; W S Cartwright; T W Hu
Journal:  Public Health Rep       Date:  1988 Jan-Feb       Impact factor: 2.792

View more
  48 in total

1.  Costs of diabetes. A methodological analysis of the literature.

Authors:  E Pagano; M Brunetti; F Tediosi; L Garattini
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

2.  The Danish approach to standards for economic evaluation methodologies.

Authors:  A Alban; M Gyldmark; A V Pedersen; J Søgaard
Journal:  Pharmacoeconomics       Date:  1997-12       Impact factor: 4.981

3.  A practical guide for calculating indirect costs of disease.

Authors:  M A Koopmanschap; F F Rutten
Journal:  Pharmacoeconomics       Date:  1996-11       Impact factor: 4.981

Review 4.  Cost-effective management of diabetic foot ulcers. A review.

Authors:  G Ragnarson-Tennvall; J Apelqvist
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

Review 5.  The economic cost of epilepsy: a review.

Authors:  M Brunetti; E Pagano; L Garattini
Journal:  Ital J Neurol Sci       Date:  1998-04

6.  A model to estimate the cost benefit of an occupational vaccination programme for influenza with Influvac in the UK.

Authors:  Roben Das Gupta; Julian F Guest
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

7.  [Annual costs of bipolar disorders in Germany].

Authors:  C Runge; H Grunze
Journal:  Nervenarzt       Date:  2004-09       Impact factor: 1.214

Review 8.  A review of health-related workplace productivity loss instruments.

Authors:  Jennifer H Lofland; Laura Pizzi; Kevin D Frick
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

9.  Costing and funding of healthcare in Australia: pharmaceuticals in context.

Authors:  T G Parry
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

10.  Economic evaluation of influenza vaccination and economic modelling. Can results be pooled?

Authors:  T Jefferson; V Demicheli
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.